Elicio Therapeutics, Inc. (ELTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Foreign currency translation adjustment | 74 | |||
| Research and development | 7,006 | |||
| General and administrative | 3,085 | |||
| Total operating expenses | 10,091 | |||
| Loss from operations | -10,091 | |||
| Interest income | 168 | |||
| Interest expense | 194 | |||
| Foreign exchange transaction (loss) gain | - | |||
| Change in fair value of warrant liabilities | 859 | |||
| Gain on sale of equipment | - | |||
| Grant income | 415 | |||
| Loss on issuance of pre-funded warrants | - | |||
| Total other (expense) income, net | -470 | |||
| Net loss | -10,561 | |||
| Comprehensive loss | -10,487 | |||
| Net loss per common share, basic (in dollars per share) | -0.66 | |||
| Net loss per common share, diluted (in dollars per share) | -0.66 | |||
| Weighted average common shares and pre-funded warrants outstanding, basic (in shares) | 16,059,423 | |||
| Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) | 16,059,423 | |||